Overall verdict
Sell
2.7/10
1-year performance
-43.33%
Score breakdown
Down 43.3% over 1 year, 12% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 0.0/10.
7 analysts.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration ; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss ; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes ;
and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates.
The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Amex
United States
CEO
Brian Culley
Founded
1990
Employees
77
Revenue / employee
189 039 USD
Next earnings
November 12, 2026
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.11%
- Bank of New York Mellon Corp0.15%
- FMR LLC0.08%
- Rest of the register97.65%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
1.99 USD
52-week low
0.88 USD
1-year performance
-43.33%
Declining
Year-to-date performance
-38.18%
Declining
Drawdown
-48.74%
Major drawdown
Position in the 52-week range
12% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 5.2 times harder.
$10,000 placed at the end of December 2000 are worth today
| Lineage Cell | $1,333 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 5.2 times as much as the world ETF.
- Worst fall:-98Â % between January 2001 and September 2006. $10,000 placed at the top fell to $216. The world ETF, at worst: -53Â %. The share has not returned to its high yet.
Lineage Cell earned less than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Lineage Cell: $1,333
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Gross margin 93.8%, the company loses 246.6% of its revenue, ROIC -57.7%, ROE -59.0%.
Net margin
-246.58%
Negative
Sector -204.15%|S&P 13.40%
Gross margin
93.81%
Exceptional
Return on equity (ROE)
-59.03%
Negative
Sector -57.81%|S&P 17.06%
Return on invested capital (ROIC)
-57.73%
Negative
Free cash flow margin (FCF)
-186.43%
Negative
Margin stability
471.7 pts
Very uneven
Revenue to net income
Growth
0.0/10Revenue down 61.3% over 1 year, 79.9% a year over 5.
Revenue (trailing 12 months)
13.1M USD
Revenue growth (1y)
-61.34%
Declining
Revenue growth (3y)
-1.00%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.8x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 15.0x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Market cap
258M USD
Financial strength
10.0/10Cash covers 2210.9% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-81.16%
Net cash
Cash
50.8M USD
Cash / market cap
19.70%
Very solid
Cash / total debt
2210.92%
Net cash
Net debt
-48.5M USD
Equity
59.8M USD
Closed daily candles, 2 years
Last close on November 10, 2026: 1.04 USD
- MM201.00
- MM501.00
- MM2001.30
- RSI 1454.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-5.19%
200-day average slope, 3 months
-14.54%
50-day average slope, 1 month
-4.28%
Price structure
Lower lows
Bullish RSI divergence
Yes
20-day volatility
3.12 % per day
Volatility change
-0.38%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.06 (7) | -0.07 (4) | 15 (7) | -34 (2) | -23 (5) |
| 2027 | -0.13 (6) | -0.14 (4) | 17 (7) | -29 (2) | -34 (5) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 772 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LRMR | 5.6 | N/A | 284M USD | Not meaningful (loss) | — | — | -135.7 % | 0.8x | -55.0 % | -21.3 % | ||
| 2 | FYB | 4.8 | 3.2 | 290M USD | Not meaningful (loss) | -41.0 % | -36.2 % | -6.2 % | -4.2x | -2.2 % | -30.3 % | ||
| 3 | ALERS | 4.3 | 4.4 | 287M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 7.1 % | ||
| 4 | NWBO | 3.5 | 4.0 | 290M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.2 % | -32.6 % | ||
| 5 | 688426 | 2.9 | 3.2 | 299M USD | Not meaningful (loss) | -35.4 % | 24.1 % | -6.0 % | — | -0.5 % | -35.6 % | ||
| 6 | SABS | 2.9 | 0.9 | 280M USD | Not meaningful (loss) | -6088.9 % | -100.0 % | -34.5 % | 1.2x | -21.0 % | -1.3 % | ||
| 7 | LCTX | 2.7 | 1.5 | 258M USD | Not meaningful (loss) | -246.6 % | -61.3 % | -57.7 % | — | -9.5 % | -43.3 % | ||
| 8 | A174900 | 2.4 | 2.6 | 298M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.0 % | -10.7 % | ||
| 9 | CRNA | 1.8 | 0.4 | 298M USD | Not meaningful (loss) | — | — | -25.6 % | 8.3x | -1.8 % | 900.5 % |
